Abbott, CamDiab and Ypsomed Partner Up To Develop Automated Insulin Delivery

They are partnering to develop and commercialize an integrated automated insulin delivery system...

Abbott, CamDiab and Ypsomed will work together to design an automated insulin delivery system for people living with diabetes. (PRNewswire image)

CamDiab and Ypsomed announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European countries.

Related Abbott Announces New Biosensors Based on Diabetes Monitoring Tech at the CES

The new integrated AID system is being designed to connect Abbott’s FreeStyle Libre 3 sensor, the world’s smallest and most accurate continuous glucose monitoring sensor with readings every minute, to CamDiab’s CamAPS FX mobile app, which connects with Ypsomed’s mylife YpsoPump – creating a smart, automated process to deliver insulin based on real-time glucose data. The connected, smart wearable solution is designed to continuously monitor a person’s glucose levels and automatically adjust and deliver the right amount of insulin at the right time, removing the guesswork of insulin dosing, Abbott said in a press release.

“Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders,” said Jared Watkin, senior vice president of Abbott’s diabetes care business. “We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”

“Poor glucose control leads to an increased risk of diabetes complications such as blindness, and heart and kidney disease. We want to help people with diabetes better manage their glucose through advanced technology. Our CamAPS FX, already approved in Europe, is a highly adaptive algorithm that when integrated with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night,” said Roman Hovorka, director of CamDiab Ltd.

The intuitive insulin pump system (Image: Ypsomed)

“We are convinced that major challenges of society can only be addressed through partnerships. We are therefore proud to expand our partners and connectivity to offer more freedom of choice in managing diabetes. When combined our mylife YpsoPump with the FreeStyle Libre 3 system and CamAPS FX advanced adaptive hybrid closed-loop app, we will be able to deliver an additional compact and lightweight AID system that is discreet and simple to use,” said Simon Michel, chief executive officer of Ypsomed.

The companies intend to complete development by end of 2022 with commercial availability expected thereafter.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Related Dexcom G6 CGM Gets Coverage in Alberta for Children and Youth Living With Diabetes

About CamDiab

CamDiab Ltd is a digital health and personalized medicine company focused on the design, development, and commercialization of its world leading, interoperable CamAPS FX closed loop app. The CamAPS FX is designed to use adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycemic control.

About Ypsomed

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years’ experience. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors, pump systems and software solutions for administering liquid medications.

Sam Draper
May 12, 2022

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

Fitbit Pay Will Now Work with NYC Subway or Bus Fares

Fitbit is now included in the growing list of device makers that support tap-to-pay in New York.

Samsung Develops Stretchable Electronic Skin for Monitoring Heart Rate

Samsung has revealed a stretchable OLED display that acts as a heart rate sensor. The wearable...

How Wearables Can Enhance E-Learning

Wearable technology is now being widely used as a learning tool. Wearables are transforming how...

Stanford Researchers Develop Elastic Light-Emitting Polymer for Wearable Displays

As part of an overarching quest to build “skin-inspired” electronics that are soft and stretchy...
Discover more